HC Wainwright & Co. Reiterates Buy on PMV Pharma, Maintains $5 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Robert Burns has reiterated a Buy rating on PMV Pharma (NASDAQ:PMVP) and maintained a $5 price target on the stock.
March 07, 2024 | 12:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Robert Burns reiterated a Buy rating on PMV Pharma and maintained a $5 price target.
The reiteration of a Buy rating and maintenance of a $5 price target by a reputable analyst could positively influence investor sentiment towards PMV Pharma, potentially leading to an increase in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100